SCHEMBL224915

SCHEMBL224915

COc1c[c]nc(OC)n1

nearest known ligand 0.38

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12614781 0.84 LMNA (0.33) LMNATDP1L3MBTL1
SCHEMBL10747342 0.82
SCHEMBL9479748 0.81 PDE4B (0.33) LMNATDP1
SCHEMBL12614786 0.81 HSD17B10 (0.32) LMNATDP1
SCHEMBL791013 0.79
SCHEMBL29002084 0.77
SCHEMBL12483414 0.74
SCHEMBL18398991 0.74
SCHEMBL8565629 0.74 ALDH1A1 (0.31)
SCHEMBL12503836 0.71 PDE10A (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9321756-B2 Azole compounds as PIM inhibitors AMGEN INC. (US) 2016-04-26 US claimed
US-9187486-B2 Bicyclic pyridazine compounds as Pim inhibitors AMGEN INC. (US) 2015-11-17 US claimed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US claimed
US-8980888-B2 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-03-17 US claimed
US-20140378447-A1 NOVEL PYRAZOLE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2014-12-25 US claimed
US-20140221344-A1 Bicyclic Pyridazine Compounds as PIM Inhibitors AMGEN INC. 2014-08-07 US claimed
US-20140187553-A1 Azole Compounds as PIM Inhibitors AMGEM INC. (US) 2014-07-03 US claimed
EP-2702063-A1 BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2014-03-05 EP claimed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US claimed
EP-2688886-A1 AZOLE COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2014-01-29 EP claimed
WO-2001054691-A1 NITRATE SALTS OF ANTIMICROBIAL AGENTS NICOX, S.A. (FR) 2001-08-02 WO claimed
US-6121201-A HETEROARYL SUBSTITUTED HALO-PYRAZOLE SUBSTITUTED DIARYL ETHERS OR THIOETHERS ISHIHARA SANGYO KAISHA, LTD. (JP) 2000-09-19 US claimed
EP-0973395-A1 DIARYL ETHERS AND PROCESSES FOR THEIR PREPARATION AND HERBICIDAL AND DESICCANT COMPOSITIONS CONTAINING THEM ISK Americas Incorporated (US) 2000-01-26 EP claimed
WO-1998041093-A1 DIARYL ETHERS AND PROCESSES FOR THEIR PREPARATION AND HERBICIDAL AND DESICCANT COMPOSITIONS CONTAINING THEM ISK AMERICAS INCORPORATED (US) 1998-09-24 WO claimed
US-5292737-A Inhibit protein kinase activity; antiinflammatory/antitumor agents; treatment for cardiovascular disorders SPHINX PHARMACEUTICALS CORPORATION (US) 1994-03-08 US claimed
EP-0096004-B1 SULFONYL(THIO)UREAS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND/OR GROWTH REGULATING AGENTS CIBA-GEIGY AG (CH) 1989-04-26 EP claimed
EP-0165032-A2 Dihydropyridine anti-ischaemic and antihypertensive agents Pfizer Limited (GB) 1985-12-18 EP claimed
US-4332796-A MICROCRYSTALS COATED WITH MIXTURES OF PHOSPHOLIPIDS AND NONIONIC SURFACTANTS LABORATORIOS BAGO S.A. (AR) 1982-06-01 US claimed
US-4202900-A Derivatives of penam-3-carboxylic acid and a pharmaceutical composition containing the same CIBA-GEIGY CORPORATION (US) 1980-05-13 US claimed
US-4167567-A Antihypertensive 4-aminoquinolines THE UPJOHN COMPANY (US) 1979-09-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378447-A1 NOVEL PYRAZOLE DERIVATIVE PDE10A, PDE3A, PDE5A LMNA 3655/4885TDP1 62/4885L3MBTL1 4637/4885
US-20140187553-A1 Azole Compounds as PIM Inhibitors PIM1, PIM3, PIM2 LMNA 2845/4885TDP1 1058/4885L3MBTL1 3074/4885
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 LMNA 2103/4885TDP1 725/4885L3MBTL1 1581/4885
US-20140221344-A1 Bicyclic Pyridazine Compounds as PIM Inhibitors PIM1, PIM2, PIM3 LMNA 1512/4885TDP1 834/4885L3MBTL1 2307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.